ATMPs Consulting Market Size, Share & Trends Analysis Report By Phase (Early-Stage Development, Clinical Development, Commercialization), By Type (Gene therapy medicinal products, Somatic cell medicinal products, Tissue-engineered medicinal products), By Region, And By Segment Forecasts, 2025-2034

ATMPs Consulting Market Size is predicted to witness a 8.6% CAGR during the forecast period for 2025-2034.

Advanced therapy medical products (ATMPs) are human medicines based on genes, tissues, or cells. They provide new and novel therapeutic options for ailments and injuries. ATMPs primarily target diseases with significant unmet medical needs. The introduction of ATMPs has altered the pharmaceutical industry as well as the illness treatment landscape. Advanced Therapy Medicinal Products (ATMPs) consulting involves seeking guidance and expertise from professionals and firms with specialized knowledge in developing, regulating, and commercialising advanced therapy medicinal products. It has opened up new avenues for the treatment of incurable diseases and cancers. Another factor driving market revenue growth is an increase in ATMP R&D spending by pharmaceutical companies, biotechnology businesses, and research institutes.

However, the global ATMPs (Advanced Therapy Medicinal Products) consultancy market was significantly impacted by the COVID-19 pandemic. The pandemic disrupted global supply lines, reducing the availability of crucial components and materials required for ATMP production. As a result, companies developing these medicines faced supply chain issues.

Competitive Landscape

Some Major Key Players In The ATMPs Consulting Market:

• Dark Horse Consulting
• PharmaLex (Acquired by AmerisourceBergen)
• ProPharma Group
• QbD Group (Michor Consulting/EUDRAC)
• Alacrita Life Science Consulting
• Voisin Consulting Life Sciences (VCLS)
• Advanced Cell & Gene Therapy
• Kinesys Consulting
• Clarkston Consulting
• Validate/DataRevive
• Asphalion
• Putnam
• Others

Market Segmentation:

The global ATMP Consulting Market is segmented on the basis of phase and type. Based on phase, the market is divided as early-stage development, clinical development, and commercialization. The market is segmented by type into gene therapy medicinal products, somatic cell medicinal products, and tissue-engineered medicinal products. 

Based On Type, The Gene Therapy Medicinal Products Segment Is Accounted As A Major Contributor In The Global Atmps Consulting Market. 

The gene therapy medicinal products category is expected to hold a major share of the global ATMP Consulting Market in 2022. This is due to increased genetic diseases such as muscular dystrophy, haemophilia, and cystic fibrosis. Gene therapy has the potential to heal many disorders by tackling the underlying genetic abnormalities that cause them. Similarly, the development of breakthrough gene editing tools such as CRISPR-Cas9 has significantly increased the growth of gene therapy income. These technologies enable accurate and efficient genome editing, which is likely to drive segment revenue growth.

The Early-Stage Development Segment Witnessed Growth At A Rapid Rate.

The early-stage development segment is projected to grow rapidly in the global ATMP Consulting Market. The Advanced Therapy Medicinal Products (ATMPs) consultancy market is characterized by various dynamic aspects that influence the industry's growth and direction. ATMPs are in high demand due to their ability to treat diseases that were previously untreatable. Early-stage consultancy must assist customers in identifying market prospects and determining the commercial viability of their cures.

The North American Global ATMP Consulting Market Holds A Significant Revenue Share In The Region.

The North American global ATMP Consulting Market is expected to record the maximum market share in revenue in the near future. A favourable regulatory environment, successful product launches, and significant investments in research and development are the primary factors leading to the region's supremacy in the market for advanced therapeutic pharmaceutical products. Furthermore, the fast-expanding number of clinical studies in this innovative therapeutic modality in the United States supports regional growth. The Asia Pacific area has experienced considerable growth in investment and support for ATMP research and development. Governments, corporate investors, and multinational collaborations are all assisting in expanding ATMPs throughout the region.

Recent Developments:

• In January 2022, PharmaLex Group announced a merger with MAP Group to enhance its market access skills and expand its footprint in the Italian market. MAP Group is Italy's top market access provider, specializing in highly innovative items such as advanced therapeutic medical products (ATMPs) for rare diseases and oncology.

• In April 2022, Voisin Consulting Life Sciences (VCLS) declared a strategic collaboration with EC Innovations in China, a renowned localization service provider with significant expertise in translating rigorously regulated life sciences and medical materials. The establishment of an alliance between VCLS and EC Innovations aimed to cultivate a durable and strong partnership, with the objective of expanding and improving the respective capacities of both organizations. This collaboration sought to elevate the quality of services offered to shared clientele.

ATMPs Consulting Market Report Scope